
Disease-Free Survival (DFS) [%]
100
80
60
40
20
0
0
20
40
60
80
100
120
Survival (Months)
Hi
Lo
Hi #patients: 60 (82.19%)
Lo #patients: 13 (17.81%)

Fig. 1

CD3G


Disease–Free Survival (DFS) [%]
0
20
40
60
80
100
0
20
40
60
80
100
120
140
Survival (Months)
Hi
Lo
Hi #patients: 55 (75.34%)
Lo #patients: 18 (24.66%)

GZMH

Fig. 2


Disease−Free Survival (DFS) [%]
100
80
60
40
20
0
0
20
40
60
80
100
120
140
Survival (Months)
Hi
Lo
Hi #patients: 52 (71.23%)
Lo #patients: 21 (28.77%)

ITGAE

Fig. 3


p−Value
5e−01
5e−02
5e−03
5e−04
20
21
22
23
24
Cutoff
Optimal HR = 4.72 Cutoff = 22.26
n HR = 1.23 Cutoff = 21.02

Fig. 4

CD3G


p-Value
1e+00
1e-01
1e-02
1e-03
1e-04
Median HR = 2 Cutoff = 20.83
Optimal HR = 5.33 Cutoff = 22.17
19
20
21
22
23
24
25
Cutoff

GZMH

Fig. 5


p-Value
1e+00
1e-02
1e-04
19
20
21
22
23
24
Cutoff
Median HR = 2.39 Cutoff = 20.92
Optimal HR = 5.06 Cutoff = 21.89
ITGAE

Fig. 6


CD8A + CTLA4
HR=Inf, pV=0.04
HR=1.45, pV=0.55
CHIMIOHiHi
NONHiHi
NONOthers
CHIMIOHiHi #patients: 14 (19.18%)
CHIMIOOthers #patients: 12 (16.44%)
NONHiHi #patients: 25 (34.25%)
NONOthers #patients: 22 (30.14%)
0
20
40
60
80
100
0
20
40
60
80
100
120
140

Fig. 7


Overall Survival (OS) [%]
100
80
60
40
20
0
0
10
20
30
40
50
60
70
Survival (Months)
CHIMIOHiHi #patients: 9 (31.03%)
CHIMIOOthers #patients: 8 (27.59%)
NONHiHi #patients: 9 (31.03%)
NONOthers #patients: 3 (10.34%)
NONOthers
CHIMIOOthers

Fig. 8


CX3CL1
IL15
CD274
VEGFA
IHH
IFNG
TSLP
CTLA4
CD247
CCR2
CD8A
CCL5
GZMA
CD3G
TBX21
IL17A
PROM1
GZMB
PDCD1
STAT1
PRF1
PF4
REN
CXCL11
ITGAE
IRF1
GZMH
CD3E
GZMK

Fig. 9


Disease-Free Survival (DFS) [%]
100
80
60
40
20
0
0
20
40
60
80
100
120
140
Survival (Months)
CHIMIOHiHi #patients: 3 (3.12%)
CHIMIOOthers #patients: 24 (25%)
NONHiHi #patients: 11 (11.46%)
NONOthers #patients: 58 (60.42%)
CHIMIOOthers
NONOthers
NONHiHi

Fig. 10


Overall Survival (OS) [%]
0
20
40
60
80
100
Survival (Months)
0
20
40
60
80
100
120
140
CHIMIOHiHi #patients: 15 (20.27%)
CHIMIOOthers #patients: 11 (14.86%)
NONHiHi #patients: 20 (27.03%)
NONOthers #patients: 28 (37.84%)
CHIMIOOthers
CHIMIOHiHi
NONOthers
NONHiHi

Fig. 11


Chimio-HiHi vs NoN-HiHi
DFS: HR = 6.36 - Pvalue=0.05
OS: HR = 4.81 - Pvalue=0.006
Chimio-Others vs NoN-Others
DFS: Pvalue=ns
OS: Pvalue=ns
CHIMIOHiHi
CHIMIOOthers
NONOthers
NONHiHi
CHIMIOHiHi #patients: 14 (18.92%)
CHIMIOOthers #patients: 12 (16.22%)
NONHiHi #patients: 22 (29.73%)
NONOthers #patients: 26 (35.14%)
Disease-Free Survival (DFS) [%]
Survival (Months)
0
20
40
60
80
100
120
140

Fig. 12


CHIMIOOthers
NONOthers
NONHiHi
CHIMIOHiHi #patients: 3 (3.12%)
CHIMIOOthers #patients: 24 (25%)
NONHiHi #patients: 12 (12.5%)
NONOthers #patients: 57 (59.38%)
Disease−Free Survival (DFS) [%]
0
20
40
60
80
100
0
20
40
60
80
100
120
140
Survival (Months)

Fig. 13


ACTOthers
ACTHiHi
OBSOthers
OBSHiHi
BS =NaN
(0.826-1.68) . HR-Corrected = 0.89 .Shrinkage Factor = 0.543
ACTHiHi #patients: 7 (7.78%)
ACTOthers #patients: 43 (47.78%)
OBSHiHi #patients: 4 (4.44%)
OBSOthers #patients: 36 (40%)
Overall Survival (OS) [%]
100
80
60
40
20
0
0
2
4
6
8
Survival (Months)

Fig. 14


ACTOthers
OBSOthers
OBSHiHi
ACTHiHi #patients: 4 (4.44%)
ACTOthers #patients: 46 (51.11%)
OBSHiHi #patients: 3 (3.33%)
OBSOthers #patients: 37 (41.11%)
Overall Survival (OS) [%]
0
20
40
60
80
100
0
2
4
6
8
Survival (Months)

Fig. 15


Overall Survival (OS) [%]
100
80
60
40
20
0
0
2
4
6
8
Survival (Months)
ACTOthers
ACTHiHi
OBSOthers
OBSHiHi
Total # pts:90
ACTHiHi #patients: 11 (12.22%)
ACTOthers #patients: 39 (43.33%)
OBSHiHi #patients: 7 (7.78%)
OBSOthers #patients: 33 (36.67%)

Fig. 16


ACTHiHi
OBSHiHi
OBSOthers
ACTOthers
ACTHiHi #patients: 39 (43.33%)
ACTOthers #patients: 11 (12.22%)
OBSHiHi #patients: 33 (36.67%)
OBSOthers #patients: 7 (7.78%)
Overall Survival (OS) [%]
100
80
60
40
20
0
0
2
4
6
8
Survival (Months)

Fig. 17


Overall Survival (OS) [%]
100
80
60
40
20
0
0
2
4
6
8
Survival (Months)
ACTOthers
ACTHiHi
OBSOthers
OBSHiHi
Total # pts:80
ACTHiHi #patients: 8 (10%)
ACTOthers #patients: 41 (45.56%)
OBSHiHi #patients: 7 (7.78%)
OBSOthers #patients: 33 (36.67%)

Fig. 18


Overall Survival (OS) [%]
100
80
60
40
20
0
0
1000
2000
3000
4000
5000
Survival (Months)
CRHiHi
CRHiHi #patients: 15 (53.57%)
CROthers #patients: 3 (10.71%)
IRHiHi #patients: 8 (28.57%)
IROthers #patients: 2 (7.14%)
IROthers
IRHiHi
CROthers

Fig. 19


Overall Survival (OS) [%]
100
80
60
40
20
0
0
1000
2000
3000
4000
5000
Survival (Months)
CRHiHi #patients: 16 (57,14%)
CROthers #patients: 2 (7,14%)
IRHiHi #patients: 7 (25%)
IROthers #patients: 3 (10,71%)
CRHiHi
CROthers
IRHiHi
IROthers

Fig. 20

REN-206367-at.cut16CR—20.6—.OS-CCL5-1405-i-at.cut16CR—1341.1—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	7	3
Others	9	33

Fisher's exact test Pvalue = 0.0057 **
χ^2 Pvalue = 0.0091 **

CTLA4-234895-at.cut16CR—16.6—.OS-CCL5-1405-i-at.cut16CR—1341.1—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	8	4
Others	8	32

Fisher's exact test Pvalue = 0.0041 ***
χ^2 Pvalue = 0.0066 **

VEGFA-211527-x-at.cut16CR—416—.OS-CD3E-205456-at.cut16CR—262.1—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	8	7
Others	8	29

Fisher's exact test Pvalue = 0.0445 *
χ^2 Pvalue = 0.0557 .

CD276-1559583-at.cut16CR—190.5—.OS-CD8A-205758-at.cut16CR—373.2—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	7	4
Others	9	32

Fisher's exact test Pvalue = 0.0227 *
χ^2 Pvalue = 0.0219 *

CTLA4-234895-at.cut16CR—16.6—.OS-CD8A-205758-at.cut16CR—373.2—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	8	4
Others	8	32

Fisher's exact test Pvalue = 0.0041 ***
χ^2 Pvalue = 0.0066 **

Fig. 21 a

PDCD1-207634-at.cut16CR—66—.OS-STAT1-209969-s-at.cut16CR—2576.4—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	6	2
Others	10	34

Fisher's exact test Pvalue = 0.0073 **
χ^2 Pvalue = 0.0114 *

PDCD1-207634-at.cut16CR—66—.OS-CXCL10-204533-at.cut16CR—2974.8—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	7	3
Others	9	33

Fisher's exact test Pvalue = 0.0057 **
χ^2 Pvalue = 0.0091 **

VEGFA-210513-s-at.cut16CR—574.4—.OS-CXCL10-204533-at.cut16CR—2974.8—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	8	4
Others	8	32

Fisher's exact test Pvalue = 0.0041 ***
χ^2 Pvalue = 0.0066 **

CD274-227458-at.cut16CR—272.6—.OS-CXCL11-210163-at.cut16CR—212.2—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	5	1
Others	11	35

Fisher's exact test Pvalue = 0.0081 **
χ^2 Pvalue = 0.0126 *

CTLA4-234895-at.cut16CR—16.6—.OS-CXCL9-203915-at.cut16CR—3106.5—.OS.merged

GROUPS:

	CR	PCR-SD-PD
HiHi	9	3
Others	7	33

Fisher's exact test Pvalue = 4e-04 ***
χ^2 Pvalue = 6e-04 ***

Fig. 21 b